Cost Utility in Second-Line Metastatic Breast Cancer

被引：0
|
作者：
Gilles Berdeaux
Patrick Hurteloup
机构：
[1] Pierre Fabre Médicament,
来源：
PharmacoEconomics | 1997年 / 11卷
关键词：
Breast Cancer; Paclitaxel; Docetaxel; Metastatic Breast Cancer; Advanced Breast Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：492 / 495
页数：3
相关论文
共 50 条
  • [1] Cost utility in second-line metastatic breast cancer
    Berdeaux, G
    Hurteloup, P
    PHARMACOECONOMICS, 1997, 11 (05) : 492 - 495
  • [2] Cost utility in second-line metastatic breast cancer - Reply
    Launois, R
    ReboulMarty, J
    Henry, B
    Bonneterre, J
    PHARMACOECONOMICS, 1997, 11 (05) : 495 - 497
  • [3] Cost Utility in Second-Line Metastatic Breast Cancer: The Authors’ Reply
    Robert Launois
    Jeanne Reboul-Marty
    Bernadette Henry
    Jacques Bonneterre
    PharmacoEconomics, 1997, 11 : 495 - 497
  • [4] A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer
    Li, N
    van Agthoven, M
    Willemse, PHB
    Uyl-de Groot, CA
    ANTI-CANCER DRUGS, 2001, 12 (06) : 533 - 540
  • [5] A cost-utility analysis of second-line chemotherapy in metastatic breast cancer - Docetaxel versus paclitaxel versus vinorelbine
    Launois, R
    ReboulMarty, J
    Henry, B
    Bonneterre, J
    PHARMACOECONOMICS, 1996, 10 (05) : 504 - 521
  • [6] Capecitabine second-line monotherapy for metastatic breast cancer
    Vasev, N.
    Maneva, L.
    Smickoska, S.
    Arsovski, O.
    Stojkovski, I.
    Milanova, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 133 - 134
  • [7] A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer
    Parmar, A.
    Richardson, M.
    Coyte, P. C.
    Cheng, S.
    Sander, B.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2020, 27 (04) : E386 - E394
  • [8] Utility of Prognostic Markers in Second-line Treatment of Metastatic Urothelial Cancer
    Raby, S. E. M.
    Conroy, R.
    Lyons, J.
    Weaver, J.
    Elliott, T.
    Choudhury, A.
    CLINICAL ONCOLOGY, 2017, 29 (11) : E206 - E206
  • [9] Treatment Choices for Second-Line Chemotherapy of Metastatic Breast Cancer
    Christoph C. Zielinski
    Breast Cancer Research and Treatment, 2003, 81 (Suppl 1) : 33 - 36
  • [10] Taxotere as second-line chemotherapy for metastatic breast cancer.
    Culine, S
    REVUE DE MEDECINE INTERNE, 1999, 20 (03): : 277 - 280
12345